These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 19961542)

  • 1. Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?
    Loo TW; Clarke DM
    Biochem Biophys Res Commun; 2005 Apr; 329(2):419-22. PubMed ID: 15737603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATP hydrolysis promotes interactions between the extracellular ends of transmembrane segments 1 and 11 of human multidrug resistance P-glycoprotein.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2005 Aug; 44(30):10250-8. PubMed ID: 16042402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors.
    Coley HM
    Methods Mol Biol; 2010; 596():341-58. PubMed ID: 19949931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P glycoprotein and the mechanism of multidrug resistance.
    Váradi A; Szakács G; Bakos E; Sarkadi B
    Novartis Found Symp; 2002; 243():54-65; discussion 65-8, 180-5. PubMed ID: 11990782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
    Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
    Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
    Gayet L; Dayan G; Barakat S; Labialle S; Michaud M; Cogne S; Mazane A; Coleman AW; Rigal D; Baggetto LG
    Biochemistry; 2005 Mar; 44(11):4499-509. PubMed ID: 15766280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generating inhibitors of P-glycoprotein: where to, now?
    Crowley E; McDevitt CA; Callaghan R
    Methods Mol Biol; 2010; 596():405-32. PubMed ID: 19949934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mamma Mia, P-glycoprotein binds again.
    Callaghan R; Gelissen IC; George AM; Hartz AMS
    FEBS Lett; 2020 Dec; 594(23):4076-4084. PubMed ID: 33022784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global alteration of the drug-binding pocket of human P-glycoprotein (ABCB1) by substitution of fifteen conserved residues reveals a negative correlation between substrate size and transport efficiency.
    Vahedi S; Chufan EE; Ambudkar SV
    Biochem Pharmacol; 2017 Nov; 143():53-64. PubMed ID: 28728917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the Recent Mouse P-Glycoprotein Structure for Structure-Based Ligand Design.
    Klepsch F; Ecker GF
    Mol Inform; 2010 Apr; 29(4):276-86. PubMed ID: 27463054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The central cavity of ABCB1 undergoes alternating access during ATP hydrolysis.
    van Wonderen JH; McMahon RM; O'Mara ML; McDevitt CA; Thomson AJ; Kerr ID; MacMillan F; Callaghan R
    FEBS J; 2014 May; 281(9):2190-2201. PubMed ID: 24597976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico model for P-glycoprotein substrate prediction: insights from molecular dynamics and in vitro studies.
    Prajapati R; Singh U; Patil A; Khomane KS; Bagul P; Bansal AK; Sangamwar AT
    J Comput Aided Mol Des; 2013 Apr; 27(4):347-63. PubMed ID: 23612916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference.
    Ansbro MR; Shukla S; Ambudkar SV; Yuspa SH; Li L
    PLoS One; 2013; 8(4):e60334. PubMed ID: 23593196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for modulatory sites at the lipid-protein interface of the human multidrug transporter P-glycoprotein.
    Mandal D; Moitra K; Ghosh D; Xia D; Dey S
    Biochemistry; 2012 Apr; 51(13):2852-66. PubMed ID: 22360349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania.
    Pérez-Victoria JM; Bavchvarov BI; Torrecillas IR; Martínez-García M; López-Martín C; Campillo M; Castanys S; Gamarro F
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3838-44. PubMed ID: 21646479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug transporters, the blood-testis barrier, and spermatogenesis.
    Su L; Mruk DD; Cheng CY
    J Endocrinol; 2011 Mar; 208(3):207-23. PubMed ID: 21134990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor agents. 280. Multidrug resistance-selective desmosdumotin B analogues.
    Nakagawa-Goto K; Chang PC; Lai CY; Hung HY; Chen TH; Wu PC; Zhu H; Sedykh A; Bastow KF; Lee KH
    J Med Chem; 2010 Sep; 53(18):6699-705. PubMed ID: 20735140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABC proteins in antigen translocation and viral inhibition.
    Parcej D; Tampé R
    Nat Chem Biol; 2010 Aug; 6(8):572-80. PubMed ID: 20644544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug efflux pumps: drug binding--gates or cavity?
    Crowley E; Callaghan R
    FEBS J; 2010 Feb; 277(3):530-9. PubMed ID: 19961542
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.